Trial
NCT00722072
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Breast Cancer
Intervention
fulvestrant
Why stopped
Sponsor pulled funding and low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-26